MY173564A - Cxcr7 receptor modulators - Google Patents

Cxcr7 receptor modulators

Info

Publication number
MY173564A
MY173564A MYPI2015704311A MYPI2015704311A MY173564A MY 173564 A MY173564 A MY 173564A MY PI2015704311 A MYPI2015704311 A MY PI2015704311A MY PI2015704311 A MYPI2015704311 A MY PI2015704311A MY 173564 A MY173564 A MY 173564A
Authority
MY
Malaysia
Prior art keywords
receptor modulators
cxcr7 receptor
formula
cxcr7
pharmaceuticals
Prior art date
Application number
MYPI2015704311A
Other languages
English (en)
Inventor
Thierry Kimmerlin
Heinz Fretz
Philippe Guerry
Francois Lehembre
Julien Pothier
Herve Siendt
Anja Valdenaire
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MY173564A publication Critical patent/MY173564A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
MYPI2015704311A 2013-05-30 2014-05-28 Cxcr7 receptor modulators MY173564A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30

Publications (1)

Publication Number Publication Date
MY173564A true MY173564A (en) 2020-02-04

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015704311A MY173564A (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Country Status (30)

Country Link
US (1) US9920010B2 (cg-RX-API-DMAC10.html)
EP (1) EP3004082B1 (cg-RX-API-DMAC10.html)
JP (1) JP6393749B2 (cg-RX-API-DMAC10.html)
KR (1) KR102302580B1 (cg-RX-API-DMAC10.html)
CN (1) CN105263924B (cg-RX-API-DMAC10.html)
AR (1) AR096490A1 (cg-RX-API-DMAC10.html)
AU (1) AU2014272718B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015030095B1 (cg-RX-API-DMAC10.html)
CA (1) CA2912133C (cg-RX-API-DMAC10.html)
CL (1) CL2015003470A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119537T1 (cg-RX-API-DMAC10.html)
DK (1) DK3004082T3 (cg-RX-API-DMAC10.html)
EA (1) EA028604B1 (cg-RX-API-DMAC10.html)
ES (1) ES2645470T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171597T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036649T2 (cg-RX-API-DMAC10.html)
IL (1) IL242782B (cg-RX-API-DMAC10.html)
LT (1) LT3004082T (cg-RX-API-DMAC10.html)
MA (1) MA38679B1 (cg-RX-API-DMAC10.html)
MX (1) MX364104B (cg-RX-API-DMAC10.html)
MY (1) MY173564A (cg-RX-API-DMAC10.html)
NO (1) NO3004082T3 (cg-RX-API-DMAC10.html)
PH (1) PH12015502632B1 (cg-RX-API-DMAC10.html)
PL (1) PL3004082T3 (cg-RX-API-DMAC10.html)
PT (1) PT3004082T (cg-RX-API-DMAC10.html)
SG (1) SG11201509057UA (cg-RX-API-DMAC10.html)
SI (1) SI3004082T1 (cg-RX-API-DMAC10.html)
TW (1) TWI640510B (cg-RX-API-DMAC10.html)
UA (1) UA118562C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014191929A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators
US20170112831A1 (en) * 2015-10-23 2017-04-27 James MERRITT Use of ccr1 antagonists as a treatment for tumors of the central nervous system
EP3490986B1 (en) * 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
RU2214405C2 (ru) 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
ATE427933T1 (de) 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
ATE486875T1 (de) * 2005-11-10 2010-11-15 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators

Also Published As

Publication number Publication date
PH12015502632A1 (en) 2016-03-07
LT3004082T (lt) 2017-10-25
EA028604B1 (ru) 2017-12-29
MA38679B1 (fr) 2019-12-31
PT3004082T (pt) 2017-11-13
HUE036649T2 (hu) 2018-07-30
SG11201509057UA (en) 2015-12-30
US9920010B2 (en) 2018-03-20
KR20160013197A (ko) 2016-02-03
AU2014272718B2 (en) 2018-06-28
BR112015030095B1 (pt) 2023-02-28
JP6393749B2 (ja) 2018-09-19
AU2014272718A1 (en) 2016-01-21
DK3004082T3 (en) 2017-10-02
WO2014191929A1 (en) 2014-12-04
CN105263924B (zh) 2018-10-19
EP3004082A1 (en) 2016-04-13
ES2645470T3 (es) 2017-12-05
EA201501163A1 (ru) 2016-06-30
CY1119537T1 (el) 2018-03-07
IL242782A0 (en) 2016-02-01
PL3004082T3 (pl) 2018-01-31
CA2912133C (en) 2021-06-22
US20160107997A1 (en) 2016-04-21
NZ715530A (en) 2020-12-18
HK1223353A1 (en) 2017-07-28
NO3004082T3 (cg-RX-API-DMAC10.html) 2017-12-30
CL2015003470A1 (es) 2016-06-17
TW201529557A (zh) 2015-08-01
EP3004082B1 (en) 2017-08-02
UA118562C2 (uk) 2019-02-11
MA38679A1 (fr) 2018-07-31
AR096490A1 (es) 2016-01-13
MX2015016429A (es) 2016-03-01
BR112015030095A2 (pt) 2022-07-12
IL242782B (en) 2019-06-30
MX364104B (es) 2019-04-12
KR102302580B1 (ko) 2021-09-15
HRP20171597T1 (hr) 2017-12-01
SI3004082T1 (sl) 2017-11-30
CN105263924A (zh) 2016-01-20
JP2016520120A (ja) 2016-07-11
PH12015502632B1 (en) 2016-03-07
TWI640510B (zh) 2018-11-11
CA2912133A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
PH12014502540A1 (en) Benzimidazole-proline derivatives
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
SG11201803699YA (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
JO3675B1 (ar) مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MY185221A (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
MY173259A (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
PH12015502632A1 (en) Cxcr7 receptor modulators
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX364610B (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MX2016006509A (es) Compuestos triciclicos de piperidina.
HK1219723A1 (zh) 作为前动力蛋白受体调节剂的派啶和氮杂䓬衍生物
IN2015DN02660A (cg-RX-API-DMAC10.html)
UA112586C2 (uk) Похідні бензімідазолпроліну